v3.26.1
Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Segment Reporting [Line Items]          
Assets $ 10,252,000   $ 10,252,000   $ 10,576,500
Interest expense (12,100) $ (12,600) (24,400) $ (24,600)  
Foreign Currency Transaction Gain (Loss), before Tax 200 (1,100) 2,600 1,600  
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 542,100 414,000 (147,700) 497,400  
Marketable Securities, Unrealized Gain (Loss) 458,000 334,400 (280,200) 366,200  
Other Nonoperating Income (Expense) 23,400 16,200 47,600 53,400  
Other Nonoperating (Income) 800 600 1,500 1,200  
Net sales 651,000 651,600 1,243,100 1,237,000  
Cost of goods sold 305,200 306,300 587,900 585,700  
Gross profit 345,800 345,300 655,200 651,300  
Selling, general and administrative expense (212,000) (207,700) (424,400) (416,500)  
Research and Development Expense (61,200) (60,500) (124,100) (134,000)  
Life Science          
Segment Reporting [Line Items]          
Net sales 252,000 262,800 480,500 491,400  
Cost of goods sold 108,500 114,500 209,400 214,700  
Depreciation, Depletion and Amortization 18,200 17,800 36,500 34,800  
Gross profit 143,500 148,300 271,100 276,700  
Clinical Diagnostics          
Segment Reporting [Line Items]          
Net sales 399,000 388,800 762,600 745,600  
Cost of goods sold 196,700 191,800 378,500 371,000  
Depreciation, Depletion and Amortization 22,900 22,800 45,500 43,900  
Gross profit 202,300 197,000 384,100 374,600  
Operating Segments          
Segment Reporting [Line Items]          
Gross profit 345,800 345,300 655,200 651,300  
Selling, general and administrative expense (212,000) (207,700) (424,400) (416,500)  
Research and Development Expense (61,200) (60,500) (124,100) (134,000)  
Operating Segments | Life Science          
Segment Reporting [Line Items]          
Assets 301,900 309,800 301,900 309,800  
Operating Segments | Clinical Diagnostics          
Segment Reporting [Line Items]          
Assets 478,700 489,000 478,700 489,000  
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment          
Segment Reporting [Line Items]          
Foreign Currency Transaction Gain (Loss), before Tax 200 (1,100) 2,600 1,600  
Marketable Securities, Unrealized Gain (Loss) 458,000 334,400 (280,200) 366,200  
Other Nonoperating Income (Expense) 23,400 16,200 47,600 53,400  
Location, Statement of Income, Balance [Axis]: us-gaap:InterestExpense | Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment          
Segment Reporting [Line Items]          
Interest expense $ (12,100) $ (12,600) $ (24,400) $ (24,600)